Trials / Withdrawn
WithdrawnNCT04652414
Corticosteroids in Community Acquired Pneumonia
Corticosteroid Treatment for Community-Acquired Pneumonia to Improve Long-term Cognition: A Pilot Randomized Controlled Trial
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Vanderbilt University Medical Center · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, blinded, placebo-controlled pilot RCT evaluating corticosteroids for the treatment of Community Acquired Pneumonia (CAP) that will enroll 100 adults hospitalized with community-acquired pneumonia. The primary goal is to assess the feasibility of proposed trial procedures for use in a subsequent phase III trial powered on 6-month cognitive outcome (MOCA-Blind score). Key outcomes are six-month cognitive and functional status, duration and severity of symptoms, and mortality.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prednisone | Prednisone 50mg will be administered enterally for 7 days. |
| DRUG | Placebo | This is a matching placebo to prednisone. |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2022-07-30
- Completion
- 2022-07-30
- First posted
- 2020-12-03
- Last updated
- 2023-02-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04652414. Inclusion in this directory is not an endorsement.